795 related articles for article (PubMed ID: 16258865)
21. [CMV infection in HIV-infected patients].
Podlasin RB
Przegl Epidemiol; 2007; 61(4):629-37. PubMed ID: 18572494
[TBL] [Abstract][Full Text] [Related]
22. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
Hung CC; Hung MN; Hsueh PR; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Huang YT; Lo YC; Hsiao CF; Chang SC
Clin Infect Dis; 2007 Sep; 45(5):e60-7. PubMed ID: 17682981
[TBL] [Abstract][Full Text] [Related]
23. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.
Gallafent JH; Buskin SE; De Turk PB; Aboulafia DM
J Clin Oncol; 2005 Feb; 23(6):1253-60. PubMed ID: 15718323
[TBL] [Abstract][Full Text] [Related]
24. Ophthalmic manifestations of HIV infections in India in the era of HAART: analysis of 100 consecutive patients evaluated at a tertiary eye care center in India.
Gharai S; Venkatesh P; Garg S; Sharma SK; Vohra R
Ophthalmic Epidemiol; 2008; 15(4):264-71. PubMed ID: 18780260
[TBL] [Abstract][Full Text] [Related]
25. Effect of highly active antiretroviral therapy (HAART) on the natural history of ocular manifestations in HIV-infected children.
Esposito S; Porta A; Bojanin J; Gualtieri L; Cesati L; Vismara E; Principi N
Eye (Lond); 2006 May; 20(5):595-7. PubMed ID: 16410815
[TBL] [Abstract][Full Text] [Related]
26. The prognosis of CMV retinitis among patients with AIDS in Serbia.
Dujić M; Jevtović Dj; Salemović D; Ranin J; Brmbolić B; Djurković-Djaković O
Biomed Pharmacother; 2008 Sep; 62(7):443-7. PubMed ID: 18243635
[TBL] [Abstract][Full Text] [Related]
27. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
[TBL] [Abstract][Full Text] [Related]
28. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
[TBL] [Abstract][Full Text] [Related]
29. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
Brumme ZL; Henrick BM; Brumme CJ; Hogg RS; Montaner JS; Harrigan PR
Antivir Ther; 2005; 10(7):849-53. PubMed ID: 16312181
[TBL] [Abstract][Full Text] [Related]
30. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.
Lim ST; Karim R; Tulpule A; Nathwani BN; Levine AM
J Clin Oncol; 2005 Nov; 23(33):8477-82. PubMed ID: 16230675
[TBL] [Abstract][Full Text] [Related]
32. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
Mussini C; Manzardo C; Johnson M; Monforte Ad; Uberti-Foppa C; Antinori A; Gill MJ; Sighinolfi L; Borghi V; Lazzarin A; Miró JM; Sabin C;
AIDS; 2008 Nov; 22(18):2461-9. PubMed ID: 19005269
[TBL] [Abstract][Full Text] [Related]
33. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis.
Martin BK; Ricks MO; Forman MS; Jabs DA;
Clin Infect Dis; 2007 Apr; 44(7):1001-8. PubMed ID: 17342657
[TBL] [Abstract][Full Text] [Related]
34. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
35. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H
Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104
[TBL] [Abstract][Full Text] [Related]
36. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
37. Seven years of HAART impact on ophthalmic management of HIV-infected patients.
Kahraman G; Krepler K; Franz C; Ries E; Maar N; Wedrich A; Rieger A; Dejaco-Ruhswurm I
Ocul Immunol Inflamm; 2005; 13(2-3):213-8. PubMed ID: 16019681
[TBL] [Abstract][Full Text] [Related]
38. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
[TBL] [Abstract][Full Text] [Related]
39. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
Polesel J; Clifford GM; Rickenbach M; Dal Maso L; Battegay M; Bouchardy C; Furrer H; Hasse B; Levi F; Probst-Hensch NM; Schmid P; Franceschi S;
AIDS; 2008 Jan; 22(2):301-6. PubMed ID: 18097233
[TBL] [Abstract][Full Text] [Related]
40. Mycobacterium kansasii in HIV patients: clarithromycin and antiretroviral effects.
Tompkins JC; Witzig RS
Int J Tuberc Lung Dis; 2007 Mar; 11(3):331-7. PubMed ID: 17352101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
